^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
QTORIN 3.9% (rapamycin topical)
i
Other names: PTX-022, PTX 022, TD201
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Ligand, Palvella Therapeutics
Drug class:
mTOR inhibitor
Related drugs:
13d
SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations (clinicaltrials.gov)
P3, N=51, Active, not recruiting, Palvella Therapeutics, Inc. | Recruiting --> Active, not recruiting
Enrollment closed
|
QTORIN 3.9% (rapamycin topical)
14d
TOIVA: A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations (clinicaltrials.gov)
P2, N=15, Active, not recruiting, Palvella Therapeutics, Inc. | Recruiting --> Active, not recruiting
Enrollment closed
|
QTORIN 3.9% (rapamycin topical)
over1year
TOIVA: A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations (clinicaltrials.gov)
P2, N=15, Recruiting, Palvella Therapeutics, Inc. | Not yet recruiting --> Recruiting
Enrollment open
|
QTORIN 3.9% (rapamycin topical)
over1year
TOIVA: A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations (clinicaltrials.gov)
P2, N=20, Not yet recruiting, Palvella Therapeutics, Inc.
New P2 trial
|
QTORIN 3.9% (rapamycin topical)
over1year
Phase 2/3 Study Evaluating the Safety and Efficacy of PTX-022 in Treatment of Adults With Pachyonychia Congenita (clinicaltrials.gov)
P2/3, N=73, Completed, Palvella Therapeutics, Inc. | Unknown status --> Completed
Trial completion
|
QTORIN 3.9% (rapamycin topical)
over1year
VAPAUS: A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita (clinicaltrials.gov)
P3, N=87, Completed, Palvella Therapeutics, Inc. | Recruiting --> Completed
Trial completion
|
QTORIN 3.9% (rapamycin topical)
over1year
VALO-2: Study Evaluating the Safety and Efficacy of PTX022 in the Treatment of Adults With Pachyonychia Congenita (clinicaltrials.gov)
P3, N=36, Completed, Palvella Therapeutics, Inc. | Active, not recruiting --> Completed | Phase classification: P3b --> P3
Trial completion • Phase classification
|
QTORIN 3.9% (rapamycin topical)
over1year
Study Evaluating the Safety and Efficacy of PTX-022 (QTORIN Sirolimus) in the Treatment of Microcystic Lymphatic Malformations (clinicaltrials.gov)
P2, N=12, Completed, Palvella Therapeutics, Inc. | Recruiting --> Completed
Trial completion
|
QTORIN 3.9% (rapamycin topical)
over1year
PALV-04: CODY: A Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel For The Prevention Of Basal Cell Carcinomas (BCCs) In Patients With Gorlin Syndrome (clinicaltrials.gov)
P2, N=73, Completed, Palvella Therapeutics, Inc. | Recruiting --> Completed | Phase classification: P2b --> P2
Trial completion • Phase classification
|
QTORIN 3.9% (rapamycin topical)
almost2years
SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations (clinicaltrials.gov)
P3, N=40, Recruiting, Palvella Therapeutics, Inc. | Not yet recruiting --> Recruiting | Trial completion date: Jan 2026 --> Jul 2026
Enrollment open • Trial completion date
|
QTORIN 3.9% (rapamycin topical)
almost2years
SELVA: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study Evaluating Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations (clinicaltrials.gov)
P3, N=50, Not yet recruiting, Palvella Therapeutics, Inc. | Initiation date: Apr 2024 --> Jul 2024
Trial initiation date
|
QTORIN 3.9% (rapamycin topical)
2years
SELVA: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study Evaluating Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations (clinicaltrials.gov)
P3, N=50, Not yet recruiting, Palvella Therapeutics, Inc.
New P3 trial
|
QTORIN 3.9% (rapamycin topical)
Share via
